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“Tell me and I will forget, teach me and I may remember, involve me and
I will learn.”
- Benjamin Franklin
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ABSTRACT
Methicillin resistant Staphylococcus aureus (MRSA) is a potentially
pathogenic bacterium that poses a serious risk in healthcare settings. MRSA can be
characterized by a genetic element, known as the staphylococcal cassette
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chromosome, which harbors the gene responsible for methicillin resistance, mecA.
MRSA can be classified into two categories: community acquired (CA) and hospital
acquired (HA). S. aureus strains represent a major health concern due to their
prevalence in healthcare facilities and their rapidly evolving antibiotic resistance.
The current study investigated the association between MRSA isolates obtained
from patients and from the intensive care units in a local hospital. Among the
bacteria isolated from the neonatal and pediatric intensive care units were
Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and members of
the Micrococcus and Bacillus genera. MRSA isolates were confirmed by a
combination of mannitol salt agar, CHROM agar, and antibiotic disc diffusion tests.
Genomic DNA was extracted from the MRSA isolates by multiplex PCR to
differentiate between CA and HA. We utilized multiple genomic markers to identify
the mecA gene, differentiate the types of MRSA, and observe if specific toxins were
present in twenty-five patient samples and eight environmental samples. In patient
samples type II (HA), type III (HA), and type IVd (CA) were confirmed. In
environmental samples type III (HA), type IVa (CA), and type V (CA) were
confirmed. Both patient and environmental samples expressed the mecA gene
indicative of MRSA. The only correlative genomic marker between patient and
environmental samples was the type III and mecA gene; however, several isolates
possessed mecA but did not match any of the types tested. Ongoing research
involves the examination of over fifty more MRSA isolates, allowing further
molecular characterization and determination of MRSA exchange in a healthcare
setting.
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Chapter 1
Introduction and Background
1.1

Multi-Drug Resistant Bacteria
9

Antimicrobials were developed by humans to reduce the impact of diseasecausing microbes, with the most common type of antimicrobials being antibiotics.
Most antibiotics target bacteria.1 Penicillin, the first commercialized antibiotic, was
discovered in 1928 by Alexander Fleming and began to be distributed to the
general public in 1945.2 The introduction of Penicillin was extremely useful for
fighting surgical and wound infections with some referring to it as the “miracle
drug”.3 Without the use of much needed antibiotics infected patients could
experience increased recovery time, increased medical expenses, limb removal due
to tissue necrosis, or even death. Unfortunately, over time certain bacteria
developed strains that exhibited resistance to penicillin, creating a need for
different antibiotics.4 Throughout the following years new antibiotics were
introduced including, but not limited to, tetracycline, erythromycin, methicillin,
gentamicin, and vancomycin.1

10

Antibiotic

Year Antibiotic
Introduced

Year Antibiotic
Resistance Identified

Penicillin

1943

1965

Tetracycline

1950

1959

Erythromycin

1953

1968

Methicillin

1960

1962

Gentamicin

1967

1979

Vancomycin

1972

1988

Levofloxacin

1996

1996

Table 1.1 A timeline showing the evolution of antibiotic resistance in relation to antibiotic
introduction.5

Antibiotic resistance occurs when bacteria are able to resist the effect of
drugs- therefore the bacteria are not killed and their growth is not inhibited.1
Throughout the 21st century antibiotic resistance has emerged to the forefront of
public healthcare concerns.6 In 2013, according to the Center for Disease Control
and Prevention, a minimum of 2 million people in the United States experienced
serious infections due to bacteria resistant to at least one antibiotic used to treat
those infections, and at least 23,000 people died directly due to antibiotic-resistant
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infections.7 In Europe approximately 400,000 people were infected with multidrugresistant bacteria leading to about 25,000 deaths in 2007.8 The growing issue of
drug resistant bacteria is a global concern that carries many implications and is a
very complex, multifactorial issue.6 There are various ways bacteria become
resistant to antibiotics. It is possible for bacteria to “neutralize” an antibiotic by
changing it in a way that essentially makes it harmless. Another way occurs when
bacteria change their outer structure preventing the antibiotic from attaching to
the bacteria it is programmed to kill.9 Overuse and misuse of antibiotics can
contribute to the development of antibiotic-resistant bacteria. A well-known group
of drug resistant bacteria are the ESKAPE pathogens (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Enterobacter species).10 They are able to “escape” the
actions of antibiotics and are the leading cause of Healthcare Associated Infections
(HAIs) throughout the world.10,11

1.2

Staphylococcus aureus
Staphylococcus aureus was discovered in the 1880s by surgeon Sir

Alexander Ogston.12 It was found to be a Gram-positive bacterium that is
responsible for causing a wide range of infections and diseases, varying from minor
skin infections to post-operative wound infections, necrotizing pneumonia, and
bacteremia.13,14 S. aureus can express resistance to many antibiotics.15,16 Early on
the mortality rate for patients infected with S. aureus was around 80%; however, in
12
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the mid 1900s S. aureus infections began to be treated with penicillin. This helped
to lower the mortality rate for infected patients. Resistance to penicillin emerged in
1942 due to the acquisition of a plasmid that encoded a penicillin-hydrolyzing
enzyme (penicillinase) and in only 18 years 80% of S. aureus strains were
unaffected by the drug.

17,18,19

However, new generations of modified beta lactam

antibiotics were briefly effective against S. aureus until 1961.

18,20,21,22

In 1961, just

two years after methicillin was introduced, which is a semisynthetic form of
penicillin, S. aureus strains emerged that were resistant to both methicillin and beta
17,18

lactam antibiotics in general due to their acquisition of the mecA gene.

S. aureus

strains have even developed resistance to other antibiotics like vancomycin if they
harbor the vanA gene, making this pathogen one of the most difficult to treat,
particularly in clinical settings where it rapidly evolves and is easily spread.

1.3

18,23,24

The mecA gene
The existence of methicillin resistant S. aureus (MRSA) has placed a

remarkable burden on the public health care system, where accurate molecular
characterization is crucial for infection control and surveillance of the bacteria.25
MRSA can be characterized by a genetic element, known as staphylococcal cassette
chromosome mec (SCCmec) that is indicated by roman numerals I to XIII.25,26,27 The
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SCCmec harbors the gene responsible for methicillin resistance, mecA, and the ccr
26

gene complex responsible for genetic mobility.

The mecA gene encodes a

penicillin-binding protein (PBP) 2A or PBP2’. Since β-lactam antibiotics (like
penicillin, or methicillin which is a semisynthetic derivative of penicillin) cannot
bind to PBP2’, synthesis of peptidoglycan layer and cell wall synthesis are able to
continue.26,27,28
In 2011 it was reported that MRSA was capable of encoding a divergent
mecA gene. This homologue known as mecC, previously known as mecALGA251, has
the potential to be misdiagnosed as methicillin sensitive S. aureus, complicating
patient management as well as MRSA surveillance.

1.4

28

Community and Hospital Acquired
During the late 1900’s two different populations of MRSA began to emerge,

known as hospital acquired (HA) and community acquired (CA).29 HA-MRSA is
usually associated with people who have had frequent or recent contact with
healthcare facilities within the past year, or have recently undergone an invasive
medical procedure.29,30,31 HA-MRSA is identified as types I, II, and III. It is a serious
infection resistant to multiple drugs and infections occur at sites including the
blood, skin, and lungs.29,32 CA-MRSA is associated with people who have not been in
the healthcare facility or had a medical procedure within the past year. CA-MRSA
typically consists of skin and soft tissue infections and is identified as types IV and

14

V MRSA.33 While SCCmecA typing helps us to differentiate CA vs. HA, determining
the true origin of each MRSA type is problematic. In recent years, researchers have
been able to identify HA-MRSA in the community and vice versa blurring the line
between HA and CA.34 The HA-MRSA could be evolving in healthcare facilities or
could be brought into healthcare facilities by patients, visitors, etc.34

Chapter 2
Materials and Methodology
2.1 Sample Collections
15

Dr. Spratt and his student research assistants, including Colin Smith, worked
with staff at Erlanger hospital to coordinate times to sample the NICU and PICU
where they would swab various areas of the environment. These areas included
stethoscopes, bed handles, bath basins, equipment drawers, computers, air ducts,
floors, etc. Thermo Fisher Scientific sterile transport swabs with liquid Stuart’s
medium were used to collect these samples. All swabs were placed on ice
immediately after being collected. Patient samples were provided directly from the
medical technology lab at Erlanger. Other than the fact that these samples came
from patients in the NICU, we are unsure of the process used by the medical
technology lab to obtain and classify these samples. 35,36

Figure 2.1. Sampling of Hospital Environment

2.2 Lab Processing
Dr. Spratt and his team processed environmental swabs collected at
Erlanger in a lab at UTC within two hours of collection. In the lab these swabs were
used to inoculate onto six different bacteria growth mediums, five classified as
selective & differential, and one non-specific growth medium:
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•

CHROM MRSA agar- selective and differential for methicillin resistant S.
aureus (MRSA)37

•

Mannitol Salt Agar (MSA)- selective and differential for Staphylococci38

•

Eosin Methylene Blue (EMB)- selective and differential for Gram negative
enterics39

•

Pseudomonas Isolation Agar (PsI)- selective and differential for
Pseudomonas40

•

MacConkey’s Agar (MAC)- selective and differential for enterics41

•

Tryptic Soy Agar (TSA)- non-specific, supports growth of many different
species42,43

2.3 MRSA Characterization
Environmental isolates from CHROM, MSA, and TSA were then line inoculated
onto MSA agar that indicates mannitol fermentation by turning agar from a deep
red color to a bright yellow.44
Antibiotic disk diffusion tests were carried out on isolates showing positive for
mannitol fermentation, to assess the strain’s resistance to four common betalactam antibiotics: Penicillin, Amoxicillin, Oxacillin, and Vancomycin.45 Confirmed
MRSA isolates were passed on to Dr. Giles and I for further characterization.
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Figure 2.2. MSA testing for S. aureus characterization

2.4 Genomic Extraction
Upon receiving an 80% glycerol stock of confirmed MRSA isolates we grew
overnight cultures to use for genomic extractions. Bacterial genetic DNA was then
extracted using a Thermo Fisher Scientific kit and following the manufacturer’s
instructions. Afterwards, quality and quantity of genomic DNA extracted was
assessed using a Nanodrop spectrophotometer.46

2.5 Multiplex Polymerase Chain Reaction
Multiplex PCR was utilized for staphylococcal cassette chromosome mec
typing with primers designed for SCCmec types, SCCmec subtypes, toxins, and the
mecA gene.47,48,49,50,51 The PCR mixture included DNA, various primers, and master
mix in a 25 µl final reaction (Figure 3) volume. Thermocycling condition were 94°C
for 5 min, followed by 10 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 90 s,
followed by 25 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 90 s, followed by
72°C for 10 min.34
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Figure 2.3. PCR Samples
Primer
mecA
SCCmec Type I
SCCmec Type II
SCCmec Type III
SCCmec Type IVa
SCCmec Type IVb
SCCmec Type IVc
SCCmec Type IVd
SCCmec Type V
Panton-Valentine
Leukocidin (PVL)
Toxic Shock
Syndrome Toxin
mecA
ccrAB

ccrC

Oligonucleotide sequence

Amplicon Size (bp)

MecA147-F (5’- GTGAAGATATACCAAGTGATT-3′)
MecA147-R (5’-ATGCGCTATAGATTGAAAGGAT-3′)
Type I-F (5’-GCTTTAAAGAGTGTCGTTACAGG-3′)
Type 1-R (5’-GTTCTCTCATAGTATGACGTCC-3′)
Type II-F (5’-CGTTGAAGATGATGAAGCG-3′)
Type II-R (5’-CGAAATCAATGGTTAATGGACC-3′)
Type III-F (5’-CCATATTGTGTACGATGCG-3′)
Type III-R (5’-CCTTAGTTGTCGTAACAGATCG-3′)
Type IVa-F (5’-GCCTTATTCGAAGAAACCG-3’)
Type IVa-R (5’-CTACTCTTCTGAAAAGCGTCG-3′)
Type IVb-F (5’-TCTGGAATTACTTCAGCTGC-3′)
Type IVb-R (5’-AAACAATATTGCTCTCCCTC-3′)
Type IVc-F (5’-ACAATATTTGTATTATCGGAGAGC-3′)
Type IVc-R (5’-TTGGTATGAGGTATTGCTGG-3′)
Type IVd-F (5’-CTCAAAATACGGACCCCAATACA-3′)
Type IVd-R (5’-TGCTCCAGTAATTGCTAAAG-3′)
Type V-F (5’-GAACATTGTTACTTAAATGAGCG-3′)
Type V-R (5’-TGAAAGTTGTACCCTTGACACC-3′)
Luk-PV-1 (5’-ATCATTAGGTAAAATGTCTGGACATGATCCA-3′)
Luk-PV-2 (5’-GCATCAAGTGTATTGGATAGCAAAAGC-3′)
GTSSTR-1 (5’-ACCCCTGTTCCCTTATCATC-3′)
GTSSTR-2 (5’-TTTTCAGTATTTGTAACGCC-3′)
mecI-F (5’-CCCTTTTTATACAATCTCGTT-3’)
mecI-R (5’-ATATCATCTGCAGAATGGG)
ccrAB-β2 (5’-ATTGCCTTGATAATAGCCITCT-3’)
ccrAB-α2 (5’-AACCTATATCATCAATCAGTACGT-3’)
ccrAB-α3 (5’-TAAAGGCATCAATGCACAAACACT-3’)
ccrAB-α4 (5’-AGCTCAAAAGCAAGCAATAGAAT-3’)
ccrC-F (5’-ATGAATTCAAAGAGCATGGC-3’)
ccrC-R (5’-GATTTAGAATTGTCGTGATTGC-3’)

147
613
398
280
776
493
200
881
325

433
326
146
700
1,000
1,600
336

Table 2.1 List of primers used in this study.26,34

2.6 Gel Electrophoresis
We made a 1.5% gel using the following procedure: put 0.6 g Agarose
19

powder into an Erlenmeyer flask, add 40 mL of TBE 1X, heat until the Agarose
powder is dissolved, then add 2 µl of 10 mg/µl EtBr before pouring the mixture into
the apparatus. After the gel in the apparatus has solidified, load the lanes with a
100 bp ladder and PCR samples and run it at 120 V.52, 53, 54, 55, 56,57

Chapter 3
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Results
3.1 Nanodrop Spectrophotometer Results
Upon completing our genomic extractions we utilized a nanodrop
spectrophotometer to analyze the concentration and purity of our DNA. We found
lysostaphin is a more efficient method of lysing S. aureus and ultimately produces a
higher yield of DNA. A 260/280 ratio of ~1.8 is generally considered “pure” for
DNA. A 260/230 ratio of ~2.0-2.2 is generally considered “pure” for nucleic acid.
Patient Samples

DNA
Concentration
(ng/μl)

260/280

260/230

1

10.1

2.88

8.99

2

12.3

2.39

2.13

3

19.0

2.25

1.91

4

17.7

2.30

2.15

5

30.9

2.30

2.24

6

18.7

1.76

1.12

7

6.50

3.24

3.16

8

38.0

2.27

2.42

Table 3.1. Results from nanodrop spectrophotometer after genomic extractions
were completed on patient samples 1-8.
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Table 3.2. Results from nanodrop spectrophotometer after genomic extractions
were completed on patient samples 9-15.

Patient Samples

DNA
Concentration
(ng/μl)

260/280

260/230

9

11.9

2.11

1.61

10

557.1

1.34

0.64

11

380.0

1.36

0.63

12

419.0

1.28

0.62

13

340.2

1.35

0.61

14

656.0

1.35

0.61

15

166.9

1.36

0.66
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Patient Samples

260/280

260/230

18

DNA
Concentration
(ng/μl)
361.8

1.96

1.20

19

205.2

2.02

1.38

20

481.1

1.60

0.80

21

107.7

1.85

1.23

22

164.3

1.97

1.43

23

197.2

1.90

1.26

24

1.61

1.68

0.93

25

64.1

1.83

1.13

26

153.9

1.32

0.71

Table 3.3. Results from nanodrop spectrophotometer after genomic extractions
were completed on patient samples 18-26
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Environmental
Samples

260/280

260/230

1c

DNA
Concentration
(ng/μl)
123.1

1.94

1.67

2c

340.7

2.00

1.19

3c

137.9

1.94

1.12

4c

53.0

2.00

1.26

5c

384.6

2.00

1.15

6c

289.3

2.02

1.23

7c

112.4

1.94

1.09

8c

60.6

2.00

1.33

Table 3.4. Results from nanodrop spectrophotometer after genomic extractions
were completed on environmental samples 1c-8c.

Control Samples

260/280

260/230

BAA-41

DNA
Concentration
(ng/μl)
120.7

1.85

1.24

BAA-2094

93.5

1.68

0.91

33592

73.5

1.78

1.18

Table 3.5. Results from nanodrop spectrophotometer after genomic extractions
were completed on control samples.

3.2 Multiplex PCR Characterization of Patient
Samples

24

Initially observing patient samples 1-8, which were all labeled as MRSA by
Erlanger hospital, 4 samples were not positive for the mecA gene that is indicative
of MRSA (Figure 3.6), samples 2, 4, 6, and 8. We repeated the multiplex PCR run
and gel with the same primers to confirm these 4 samples were negative for mecA.
In this run only 2 samples, samples 4 and 8, were negative for the mecA gene
(Figure 3.7). Diving into the literature for answers we found there is a divergent
mecA gene known as mecLGA251, also referred to as mecC. After finding this out, we
purchased the appropriate primers and tested samples 1-8 for mecLGA251, but
samples 4 and 8 were negative for mecA and mecLGA251 (Figure 3.8). Due to this we
did not believe patient samples 4 and 8 were MRSA, but suspected they were MSSA.

Figure 3.1. Gel of patient samples 1-8
from January 18th, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V
and mecA1417. The mecA gene is positive
for samples 1, 3, 5, and 7. The mecA gene is
negative for samples 2, 4, 6, and 8.

25

Figure 3.2. Gel of patient samples 1-8 from January 20th, 2017. Primers used are as
follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is positive
for samples 1, 2, 3, 5, 6, and 7. The mecA gene is negative for samples 4 and 8. In
patient samples 2, 3, and 5 a strong band is seen at ~900 bp, indicating type IVd. In
patient sample 6 there is a strong band at ~400 bp, indicating type II.
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Figure 3.3. Gel of patient samples 1-8 from November 6th, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V mecA1417, and mecLGA251. The mecA
gene is positive for samples 1, 2, 3, 5, 6, and 7. The mecA and mecLGA251 gene is
negative for patient samples 4 and 8. In patient sample 6 there is a strong band at
~400 bp, indicating type II.
As far as SCCmec types, throughout these 3 Multiplex PCR runs and gels we
identified patient samples 2, 3, and 5 to be positive for type IVd and patient sample
6 to be positive for type II (Figures 3.1, 3.2, 3.3).
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After characterizing patient samples 1-8, we moved on to samples 9-15.
Samples 9-13 were labeled as MRSA and samples 14 and 15 were labeled MSSA by
Erlanger hospital. In our first gel our results were what we expected them to be, the
mecA gene was positive for samples 9-13 and negative for samples 14 and 15
(Figure 3.4). However, there were no types observed. We believed this was
possibly due to a lower quality gel imager and decided to repeat the run. Our
findings regarding the mecA gene were consistent, but we observed type IVa in
sample 11 and type II in sample 12 (Figure 3.5) on our second run. To confirm
these findings an identical run was completed a third time. Our findings were
consistent with what was found in our second run, but additionally sample 10 was
positive for IVd (Figure 3.6).

Figure 3.4. Gel of patient
samples 9-15 from
February 10th, 2017.
Primers used are as
follows: type I, II, III, IVa,
IVb, IVc, IVd, V and
mecA1417. The mecA gene
is positive for samples 9,
10, 11, 12, and 13. The
mecA gene is negative for
samples 14 and 15.
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Figure 3.5. Gel of patient samples 9-15 from February 20th, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is
positive for samples 9, 10, 11, 12, and 13. The mecA gene is negative for samples 14
and 15. In patient sample 11 a strong band is seen at ~800 bp, indicating type IVa.
In patient sample 12 a strong band is present at ~400 bp, indicating type II.
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Figure 3.6. Gel of patient samples 9-15 from February 25th, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is
positive for samples 9, 10, 11, 12, and 13. The mecA gene is negative for samples 14
and 15. In patient sample 10 a strong band is seen at ~900 bp, indicating type IVd.
In patient sample 11 a strong band is seen at ~800 bp, indicating type IVa. In
patient sample 12 a strong band is present at ~400 bp, indicating type II.
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Although patient samples 14 and 15 were labeled as MSSA, not MRSA, by
Erlanger hospital we wanted to confirm that they were not MRSA. Testing for the
mecA and mecLGA251 would allow us to confirm this. Samples 14 and 15 tested
negative for both mecA and mecLGA251, from this we determined they were in fact
MSSA (Figure 3.12). We also streaked patient samples 14 and 15 on CHROM MRSA
agar, since it is a good indicator of MRSA with the mecA gene (Section 3.5).

Figure 3.7. Gel of patient samples 9-15 from November 8th, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V mecA1417, and mecLGA251. The mecA
gene is positive for samples 9, 10, 11, 12, and 13. The mecA and mecLGA251 gene is
negative for patient samples 14 and 15. In patient sample 12 there is a strong band
at ~400 bp, indicating type II.
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We completed a large gel consisting of patient samples 1-15. Samples 4, 8,
14, and 15 were negative for mecA, which was expected. We tested positive for
types II and IVd, but did not test positive for IVa. This could have been due to
various reasons (Figure 3.8).

Figure 3.8. Gel of patient samples 1-15 from February 22nd, 2017. Primers used are
as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is
positive for samples all samples except 4, 8, 14, and 15. In patient samples 2, 3, and
5 a strong band is present at ~880 bp, indicating type IVd. In patient samples 6 and
12 a strong band is present at ~400 bp, indicating type II.
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In December 2017 we received ~50 new patient samples. After preforming
genomic extractions on our new samples we were able to run multiplex PCR and
gels on them. We tested patient samples 18-25 with our standard set of primers
(mecA1417, types I-IVd), but left out type V (~325 bp) so we could observe if TSST
(Toxic Shock Syndrome Toxin, a virulence factor) was present (~326 bp). The two
are too close in size to differentiate if a sample was to test positive. All samples
were positive for mecA. No samples were positive for TSST (Figure 3.9).

Figure 3.9. Gel of patient samples 18-25 from February 16th, 2018. Primers used
are as follows: type I, II, III, IVa, IVb, IVc, IVd, mecA1417, and TSST. The mecA gene
is positive for samples. No samples were positive for TSST.
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We repeated this run, but used type V instead of the TSST primer. Our
results regarding mecA were consistent, but we also had patient samples 22 and 23
test positive for type III at ~280 bp. No samples were positive for type V (Figure
3.10).

Figure 3.10. Gel of patient samples 18-25 from February 23rd, 2017. Primers used
are as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The mecA gene is
positive for all samples. samples 22 and 23 a band is present at ~280, indicating
type III.
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3.3 Multiplex PCR Characterization of
Environmental Samples
Environmental samples, 1c-8c, were observed using 2 sets of primers. In
lanes 1-8 we used our standard set of primers (mecA1417, types I-V) and in lanes 916 we used unique mix found in a different paper. In lanes 1-8 there mecA gene was
positive for samples 4-8, but we decided to run another gel in hopes to see stronger
bands in samples 1-3. Additionally, sample 4 was positive for type IVa (Figure
3.11).

Figure 3.11. Gel of environmental
samples 1c-8c from March 29th,
2017. Two sets of primers were
used. In lanes 1-8 the primers used
are as follows: type I, II, III, IVa, IVb,
IVc, IVd, V and mecA1417. In lanes
9-16 the primers used are as
follows: mecA1417, mecI, ISI272,
ccrAB-α2, ccrAB-α3, ccrAB-α4,
ccrAB-β2, and ccrC. In
environmental sample 4 a strong
band is seen at ~800 bp, indicating
type IVa. In lanes 9, 12, 15, and 16
bands are present at ~146 bp,
indicating mecA. In lanes 9, 12,14,
and 16 bands are present at~336
bp, indicating ccrC gene which is
harbored by MRSA. 26,34
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A second gel was run on environmental samples 1c-8c again, this time only
using 1 set of primers (mecA1417, types I-V). Samples 1c and 4c-8c were positive
for mecA. Samples 2c and 3c were negative for mecA despite being previously
determined as MRSA by Dr. Spratt’s lab. Sample 4c was positive for type IVa.
Sample 6c was positive for type III. Sample 8c is positive type V (Figure 3.12).

Figure 3.12. Gel of environmental samples 1c-8c from September 22nd, 2017.
Primers used are as follows: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. In
environmental sample 4c a strong band is present at ~800 bp, indicating type IVa.
In environmental sample 6c a strong band is present at ~280 bp, indicating type III.
In environmental sample 8c a strong band is present at ~325 indicating type V.
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Since environmental samples 2c and 3c were expected to be MRSA, we did a
third run suspecting the two samples would be positive for mecA. Additionally, we
used PVL (Panton-Valentine Leukocidin, a virulence factor,~433 bp) and TSST
(~326 bp) primers in place of types IVb (~493) and V (~325), respectively. The
mecA gene was present in all samples. No samples were positive for PVL or TSST
(Figure 3.13).

Figure 3.13. Gel of environmental samples 1c-8c from December 2nd, 2017.
Primers used are as follows: type I, II, III, IVa, IVc, IVd, mecA1417, PVL, and TSST.
Type IVb and V were not tested for as their bp are too close in size to PVL and TSST
to differentiate. No environmental samples tested positive for PVL or TSST.
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3.4 Multiplex PCR Characterization of Control
Samples
Later into the study, we purchased control samples of MRSA from the
American Type Culture Collection to ensure our primers were operating properly.
We purchased BAA-41, BAA-2094, and 33592, which were controls for types II, III,
and V, respectively. We ran a PCR and gel with primers for type II, III, V, and
mecA1417. BAA-41 and BAA-2094 did not test positive for their expected types.
This could be due to human error and will be repeated at a later date (Figure 3.14).

Figure 3.14. Gel of control samples (BAA-41, BAA-2094, and 33592) from March
6th, 2018. Primers used are as follows: type II, III, V, and mecA1417. The mecA gene
is positive for samples BAA-2094 and 33592. Sample 33592 was positive for type V,
which was expected. BAA-41 and BAA-2094 were negative for, respectively, type II
and III, which was not expected.
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3.5 Plates
After repeated multiplex PCR and gels to identify mecA or mecLGA251 in
patient samples 4 and 8 were consistently negative we decided to streak plates and
compare them to known MSSA samples, samples 14 and 15. Working with Colin
Smith, utilizing visual examination of the plates combined with repeated negative
results from gels we determined samples 4 and 8 were also MSSA, not MRSA.

Patient Sample 4

Patient Sample 14

Patient Sample 8

Patient Sample 15

Figure 3.15. Patient samples 4, 8, 14, and 15 streaked onto agar plates were
determined to be methicillin-sensitive S. aureus.
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3.6 Pie Graphs
Patient Isolates

17%

MRSA
MSSA
83%

Figure 3.16. Comparison of MRSA and MSSA patient isolates.

Patient MRSA Types
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Type II
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Type III
12%
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Type IVd
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Figure 3.17. Types found within MRSA patient isolates.
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Environmental MRSA Types
Type I
Type II

12%

Type III
Type IVa
12%

Type IVb
Type IVc

63%
13%

Type IVd
Type V
PVL
TSST
Not Typed

Figure 3.18. Types found within MRSA patient isolates.
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Chapter 4
Discussion and Future Direction
Methicillin resistant S. aureus is a major public health concern. A patient
infected with MRSA can experience many complications, with some even being life
threatening. Due to this bacteria’s severity, it is imperative for researchers to have a
thorough understanding of how it is transferred, different types present, if it is
carrying virulence factors, and so forth.58
We had multiple goals in this research: to confirm if isolates were MRSA or
not, identify if there was any correlation between patient and environmental
isolates, and to determine if any isolates had virulence factors.
Beginning with our patient samples we used a standard set of primers
consisting of the following: type I, II, III, IVa, IVb, IVc, IVd, V and mecA1417. The
mecA1417 gene is indicative of MRSA allowing us to confirm if isolates were MRSA
or not. Patient samples 4, 8, 14, and 15 were all negative for mecA1417. We were
not surprised samples 14 and 15 were negative as they were labeled methicillinsensitive, not resistant, S. aureus (MSSA) when we received them. However, patient
samples 4 and 8 were labeled MRSA, which prompted us to rerun our PCR and gel.
Again we had negative results for mecA1417 with patient samples 4 and 8, but it
was possible that these samples had the divergent gene for mecA, known as
mecALGA251. Patient samples 4 and 8 also tested negative for mecALGA251 leading us to
believe they were not MRSA, but instead MSSA. We streaked plates with our two
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known methicillin-sensitive samples, 14 and 15, and what we believed to be
methicillin-sensitive samples, 4 and 8. After allowing these samples to grow and
upon visual examination it was determined samples 4, 8, 14, and 15 were MSSA.
Our patient samples exhibited various types of MRSA. Patient samples 2, 3,
5, and 10 were positive for type IVd. Patient samples 6 and 12 were positive for
type II. Patient sample 11 was positive for type IVa. Patient samples 22 and 23 were
positive for type III. Patient samples 16 and 17 were contaminated during our
process and no longer viable for observation. The remaining MRSA patient samples:
1, 9, 18, 19, 20, 21, 24, and 25 were not typed. Due to time constraints, we only
observed types I-V, but there is typing available up to type X.59,60
Our 8 environmental samples were all positive for mecA1417.
Environmental sample 4 was positive for type IVa. Environmental sample 6 was
positive for type III. Environmental sample 8 was positive for type V. The
remaining MRSA environmental samples: 1, 2, 3, 5, and 7 were not typed, but may
be types VI-X that were not tested for. Types III and IVa were present in both
patient and environmental samples. This could indicate transmission from various
objects or surfaces to patients.60
Our most common type of MRSA found was type IV. Type IV MRSA has also
been found in other countries such as Brazil, Denmark.61,62 Additionally in other
studies where U.S. isolates were observed, type IV isolates were a common
finding.63
The limiting factor to this study was the small amount of environmental
samples available. If there were a larger amount of environmental samples it is
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possible that additional correlations would have been found between patient and
environmental samples.
In future studies researchers should examine the 42 new patient samples we
have received from Erlanger hospital’s NICU and PICU. These should be examined
for mecA1417, mecALGA251, and type I-X. Additionally, more environmental samples
should be obtained with the known location (stethoscope, crib, air duct, floors, etc.)
in order to observe more detailed correlations between patient and environmental
samples, as well as identify if certain locations have higher incidences of a certain
type or virulence factors than others.
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